DrugCite
Search

VINBLASTINE SULFATE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Vinblastine Sulfate Adverse Events Reported to the FDA Over Time

How are Vinblastine Sulfate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Vinblastine Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Vinblastine Sulfate is flagged as the suspect drug causing the adverse event.

Most Common Vinblastine Sulfate Adverse Events Reported to the FDA

What are the most common Vinblastine Sulfate adverse events reported to the FDA?

Pulmonary Toxicity
126 (3.71%)
Neutropenia
82 (2.41%)
Febrile Neutropenia
77 (2.27%)
Pancytopenia
59 (1.74%)
Dyspnoea
48 (1.41%)
Vomiting
45 (1.32%)
Nausea
43 (1.27%)
Pyrexia
42 (1.24%)
Sepsis
42 (1.24%)
Interstitial Lung Disease
30 (.88%)
Mucosal Inflammation
30 (.88%)
Show More Show More
Hypothyroidism
29 (.85%)
Neuropathy Peripheral
29 (.85%)
Dehydration
25 (.74%)
Fatigue
25 (.74%)
Pneumonia
24 (.71%)
Anaemia
23 (.68%)
Renal Failure Acute
23 (.68%)
Abdominal Pain
21 (.62%)
Acute Myeloid Leukaemia
21 (.62%)
Drug Toxicity
21 (.62%)
Thrombocytopenia
21 (.62%)
White Blood Cell Count Decreased
21 (.62%)
Azoospermia
20 (.59%)
Drug Interaction
20 (.59%)
Testicular Disorder
19 (.56%)
Diarrhoea
18 (.53%)
Hypocalcaemia
18 (.53%)
Pneumonitis
18 (.53%)
Pulmonary Embolism
18 (.53%)
Tachycardia
18 (.53%)
Hyponatraemia
17 (.5%)
Leukopenia
17 (.5%)
Pericardial Effusion
17 (.5%)
Renal Failure
17 (.5%)
Death
16 (.47%)
Drug Exposure During Pregnancy
16 (.47%)
Lung Infiltration
16 (.47%)
Hypoxia
15 (.44%)
Lymphadenopathy
15 (.44%)
Neurotoxicity
15 (.44%)
Progressive Multifocal Leukoencepha...
15 (.44%)
Septic Shock
15 (.44%)
Hypotension
14 (.41%)
Pneumothorax
14 (.41%)
Convulsion
13 (.38%)
Deep Vein Thrombosis
13 (.38%)
General Physical Health Deteriorati...
13 (.38%)
Hypoaesthesia
13 (.38%)
Ileus
13 (.38%)
Infection
13 (.38%)
Neutrophil Count Decreased
13 (.38%)
Polyneuropathy
13 (.38%)
Respiratory Failure
13 (.38%)
Constipation
12 (.35%)
Disease Progression
12 (.35%)
Hypertension
12 (.35%)
Lung Disorder
12 (.35%)
Lung Infection
12 (.35%)
Oedema Peripheral
12 (.35%)
Asthenia
11 (.32%)
Chills
11 (.32%)
Haematotoxicity
11 (.32%)
Myelodysplastic Syndrome
11 (.32%)
Pain
11 (.32%)
Platelet Count Decreased
11 (.32%)
Acute Respiratory Failure
10 (.29%)
Alanine Aminotransferase Increased
10 (.29%)
Coagulopathy
10 (.29%)
Cough
10 (.29%)
Haemoglobin Decreased
10 (.29%)
Liver Function Test Abnormal
10 (.29%)
Pneumocystis Jiroveci Pneumonia
10 (.29%)
Weight Decreased
10 (.29%)
Atelectasis
9 (.26%)
Cardiomyopathy
9 (.26%)
Encephalopathy
9 (.26%)
Foetal Growth Retardation
9 (.26%)
Multi-organ Failure
9 (.26%)
Pulmonary Fibrosis
9 (.26%)
Respiratory Disorder
9 (.26%)
Respiratory Distress
9 (.26%)
Subcutaneous Emphysema
9 (.26%)
Acute Lymphocytic Leukaemia
8 (.24%)
Aphthous Stomatitis
8 (.24%)
Back Pain
8 (.24%)
Carbon Monoxide Diffusing Capacity ...
8 (.24%)
Drug Ineffective
8 (.24%)
Gait Disturbance
8 (.24%)
Histiocytosis Haematophagic
8 (.24%)
Malignant Neoplasm Progression
8 (.24%)
Neutropenic Sepsis
8 (.24%)
Oligohydramnios
8 (.24%)
Onychomycosis
8 (.24%)
Pain In Extremity
8 (.24%)
Paraesthesia
8 (.24%)
Premature Baby
8 (.24%)
Pulmonary Function Test Decreased
8 (.24%)
Pulmonary Oedema
8 (.24%)
Streptococcal Bacteraemia
8 (.24%)
Tumour Lysis Syndrome
8 (.24%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Vinblastine Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vinblastine Sulfate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Vinblastine Sulfate

What are the most common Vinblastine Sulfate adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Vinblastine Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vinblastine Sulfate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Vinblastine Sulfate According to Those Reporting Adverse Events

Why are people taking Vinblastine Sulfate, according to those reporting adverse events to the FDA?

Hodgkins Disease
617
Bladder Cancer
31
Langerhans Cell Histiocytosis
27
Non-hodgkins Lymphoma
27
Diffuse Large B-cell Lymphoma
26
Chemotherapy
19
Show More Show More
Desmoid Tumour
16
Product Used For Unknown Indication
16
Ovarian Cancer
15
Testis Cancer
15
Lymphoma
15
Transitional Cell Carcinoma
14
Drug Use For Unknown Indication
11
Testicular Germ Cell Cancer
10
Metastatic Malignant Melanoma
10
Metastatic Renal Cell Carcinoma
9
Hodgkins Disease Nodular Sclerosis ...
9
Pseudolymphoma
8
Malignant Melanoma
8
Hodgkins Disease Stage Iv
7
Choriocarcinoma
7
Hodgkins Disease Stage Iii
7
Hodgkins Disease Stage Ii
7
Neoplasm Malignant
6
Langerhans Cell Granulomatosis
6
Malignant Neoplasm Of Renal Pelvis
5
Malignant Histiocytosis
5
Ovarian Germ Cell Endodermal Sinus ...
5
Germ Cell Cancer
5
Castlemans Disease
4
Anaplastic Large Cell Lymphoma T- A...
4
Ewings Sarcoma
4
Sarcoma
4
Renal Cell Carcinoma
4
Non-small Cell Lung Cancer
3
Xanthogranuloma
3
Drug Exposure During Pregnancy
3
Non-hodgkins Lymphoma Stage Iv
3
Testicular Neoplasm
3
Brain Neoplasm
3
Lung Neoplasm Malignant
3
Renal Cancer
3
Prostate Cancer Metastatic
3
Acute Lymphocytic Leukaemia
3
Anal Cancer
3
Teratoma
2
Ovarian Neoplasm
2
Angiosarcoma
2
Small Cell Carcinoma
2
Hodgkins Disease Mixed Cellularity ...
2
Seminoma
2

Drug Labels

LabelLabelerEffective
Vinblastine SulfateBedford Laboratories02-APR-10
Vinblastine SulfateAPP Pharmaceuticals, LLC17-JAN-12

Vinblastine Sulfate Case Reports

What Vinblastine Sulfate safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Vinblastine Sulfate. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Vinblastine Sulfate.